BioWorld

April 5, 2002

CancerVax’s Second Round Raises $55M For Canvaxin

CancerVax Corp., a young company studying a vaccine for melanoma and colon cancer, on Monday said it raised $55 million in its second round of financing through the private placement of preferred stock. (BioWorld Today) Read More

LifeTime Acquires Cancer Product From Dovetail For Equity Position

Rice, First Grain Ever Sequenced, Provides Ideal Biotech Research Model For Improving Multi-Cereals

GenPhar Reveals Platform, Has Partnerships With Army, NIH

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...